Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 62 publications.

Herring WL, Gallagher ME, Shah N, Morse KC, Mladsi D, Dong OM, Chawla A, Leiding JW, Zhang L, Paramore C, Andemariam B. Cost-effectiveness of lovotibeglogene autotemcel (lovo-cel) gene therapy for patients with sickle cell disease and recurrent vaso-occlusive events in the United States. Pharmacoeconomics. 2024 Jun;42(6):693-714. doi: 10.1007/s40273-024-01385-9

Brogan AJ, Davis AE, Mellott CE, Fraysse J, Metzner AA, Oglesby AK. Cost-effectiveness of cabotegravir long-acting for HIV pre-exposure prophylaxis in the United States. Pharmacoeconomics. 2024 Apr;42(4):447-61. doi: 10.1007/s40273-023-01342-y

Mikkelsen EM, Ulrichsen SP, Johannesen BR, Laursen ASD, Wise LA, Hatch EE, Rothman KJ, Wesselink AK, Crowe H, Sorensen HT. Preconception use of antibiotics and fecundability: a Danish prospective cohort study. Fertil Steril. 2023 Sep 1;120(3 Pt 2):650-9. doi: 10.1016/j.fertnstert.2023.04.030

Joseph MD, Hatch EE, Koenig MR, Eisenberg ML, Wang TR, Sommer GJ, Stuver SO, Rothman KJ, Wise LA. A North American study of anthropometric factors and semen quality. Fertil Steril. 2023 Sep 1;120(3 Pt 2):586-96. doi: 10.1016/j.fertnstert.2023.04.040.

Wise LA, Wang TR, Stanford JB, Wesselink AK, Ncube CN, Rothman KJ, Murray EJ. A randomized trial of web-based fertility-tracking software and fecundability. Fertil Steril. 2023 Jun 10;119(6):1045-56. doi: 10.1016/j.fertnstert.2023.02.005

Karim S, Craig BM, Vass C, Groothuis-Oudshoorn CGM. Current practices for accounting for preference heterogeneity in health-related discrete choice experiments: a systematic review. Pharmacoeconomics. 2022 Oct 1;40(10):943-56. doi: 10.1007/s40273-022-01178-y

Spelman T, Herring WL, Zhang Y, Tempest M, Pearson I, Freudensprung U, Acosta C, Dort T, Hyde R, Havrdova E, Horakova D, Trojano M, De Luca G, Lugaresi A, Izquierdo G, Grammond P, Duquette P, Alroughani R, Pucci E, Granella F, Lechner-Scott J, Sola P, Ferraro D, Grand’Maison F, Terzi M, Rozsa C, Boz C, Hupperts R, Van Pesch V, Oreja-Guevara C, van der Walt A, Jokubaitis VG, Kalincik T, Butzkueven H. Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in patients with inadequate response to disease-modifying therapies in relapsing-remitting multiple sclerosis in the United Kingdom. Pharmacoeconomics. 2022 Mar;40(3):323-39. doi: 10.1007/s40273-021-01106-6.

Dorgali MV, Longo A, Vass C, Shields G, Harrison R, Scarpa R, Boeri M. A general public study on preferences and welfare impacts of antimicrobial resistance in the United Kingdom. Pharmacoeconomics. 2022 Jan;40(1):65-76. doi: 10.1007/s40273-021-01076-9

Yland JJ, Eisenberg ML, Hatch EE, Rothman KJ, McKinnon CJ, Nillni YI, Sommer GJ, Wang TR, Wise LA. A North American prospective study of depression, psychotropic medication use, and semen quality. Fertil Steril. 2021 Sep;116(3):833-42. doi: 10.1016/j.fertnstert.2021.03.052

Estes SJ, Poulos C, Xu Y, Botha W, Leach CA, Wrobleski KK, Gordon K, Missmer SA. A discrete choice experiment study of physicians' preference for treatments for endometriosis-associated pain - fertility and sterility (fertstert.org). Presented at the 2021 American Society for Reproductive Medicine Scientific Congress & Expo; October 17, 2021. Baltimore, MD. [abstract] Fertil Steril. 2021 Sep 1; 116(3):e205. doi: 10.1016/j.fertnstert.2021.07.561

Brogan AJ, Talbird SE, Davis AE, La EM, Kumar PN. The cost-effectiveness and budget impact of ibalizumab-uiyk for adults with multidrug-resistant HIV-1 infection in the United States. Pharmacoeconomics. 2021 Apr;39(4):421-32. doi: 10.1007/s40273-020-00992-6

Mamolo C, Welch V, Walter RB, Cappelleri JC, Brockbank J, Cawson M, Knight C, Wilson M. Budget impact analysis of gemtuzumab ozogamicin for the treatment of CD33-positive acute myeloid leukemia. Pharmacoeconomics. 2021 Jan;39(1):121-31. doi: 10.1007/s40273-020-00976-6

Reed SD, Saltus CW, Getahun D, Schoendorf J, Armstrong MA, Peipert JF, Raine-Bennett TR, Ritchey ME, Ichikawa LE, Zhou X, Fassett MJ, Alabaster A, Xie F, Merchant M, Chiu VY, Shi JM, Frenz A-K, Im TM, Takhar HS, Lynen R, Asiimwe A, Anthony MS. Menorrhagia and risk of intrauterine device (IUD) expulsion and uterine perforation: results from the APEX IUD study. Presented at the Virtual 76th Scientific Congress of the American Society for Reproductive Medicine (ASRM); October 17, 2020. [abstract] Fertil Steril. 2020 Sep 1; 114(3 Suppl):e12. doi: 10.1016/j.fertnstert.2020.08.059

Carrico J, Zhao Y, Jia X, Brodtkorb TH, Mendelsohn A, Lowry S. The budget impact of introducing tildrakizumab to a United States health plan for managing moderate-to-severe plaque psoriasis. Pharmacoeconomics. 2020 Mar 26.

Stanford JB, Willis SK, Hatch EE, Rothman KJ, Wise LA. Fecundability in relation to use of fertility awareness indicators in a North American preconception cohort study. Fertil Steril. 2019 Nov;112(5):892-9. doi: 10.1016/j.fertnstert.2019.06.036

Zuluaga-Sanchez S, Teynor M, Knight C, Thompson R, Lundqvist T, Ekelund M, Forsmark A, Vickers AD, Lloyd A. Cost effectiveness of nusinersen in the treatment of patients with infantile-onset and later-onset spinal muscular atrophy in Sweden. Pharmacoeconomics. 2019 Jun;37(6):845-65. doi: 10.1007/s40273-019-00769-6

Willis SK, Hatch EE, Wesselink AK, Rothman KJ, Mikkelsen EM, Wise LA. Female sleep patterns, shift work, and fecundability in a North American preconception cohort study. Fertil Steril. 2019 Jun;111(6):1201-1210. doi: 10.1016/j.fertnstert.2019.01.037

Soekhal V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019 Feb;37(2):201-26. doi: 10.1007/s40273-018-0734-2

Poulos C, Soliman A, Renz C, Posner J, Bhattacharya M, Agarwal SK. A discrete choice experiment study of patient preferences regarding treatments for endometriosis-associated pain. Poster presented at the ASRM 2018 Scientific Congress & Expo; October 10, 2018. Denver, CO. [abstract] Fertil Steril. 2018 Sep; 110(4 Supplement):e389. doi: 10.1016/j.fertnstert.2018.07.1087

Emery P, van Keep M, Beard S, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Marzo-Ortega H. Cost effectiveness of secukinumab for the treatment of active ankylosing spondylitis in the UK. Pharmacoeconomics. 2018 Aug;36(8):1015-27. doi: 10.1007/s40273-018-0675-9

Buchanan V, Sullivan W, Graham C, Miles L, Jugl SM, Gunda P, Halliday A, Kirkham B. Cost effectiveness of secukinumab for the treatment of active psoriatic arthritis in the UK. Pharmacoeconomics. 2018 Jul;36(7):867-78. doi: 10.1007/s40273-018-0674-x.

Wise LA, Rothman KJ, Wesselink AK, Mikkelsen EM, Sorensen HT, McKinnon CJ, Hatch EE. Male sleep duration and fecundability in a North American preconception cohort study. Fertil Steril. 2018 Mar;109(3):453-9. doi: 10.1016/j.fertnstert.2017.11.037

Vass CM, Payne K. Using discrete choice experiments to inform the benefit-risk assessment of medicines: are we ready yet? Pharmacoeconomics. 2017 Sep;35(9):859-66. doi: 10.1007/s40273-017-0518-0.

Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or knee replacement: a systematic review. Pharmacoeconomics. 2017 May;35(5):517-35. doi: 10.1007/s40273-017-0486-4

Mauskopf J, Earnshaw S. A methodological review of US budget-impact models for new drugs. Pharmacoeconomics. 2016 Nov;34(11):1111-31. doi: 10.1007/s40273-016-0426-8

Tappenden P, Ren S, Archer R, Harvey R, James MM, Basarir H, Stevens J, Lobo A, Hoque S. A model-based economic evaluation of biologic and non-biologic options for the treatment of adults with moderately-to-severely active ulcerative colitis after the failure of conventional therapy. Pharmacoeconomics. 2016 Oct;34(10):1023-38. doi: 10.1007/s40273-016-0409-9.

Graham J, Mcbride D, Stull D, Halliday A, Alexopoulos ST, Balp MM, Griffiths M, Agirrezabal I, Zuberbier T, Brennan A. Cost utility of omalizumab compared with standard of care for the treatment of chronic spontaneous urticaria. Pharmacoeconomics. 2016 Aug;34(8):815-27. doi: 10.1007/s40273-016-0412-1

McKinnon CJ, Hatch EE, Rothman KJ, Mikkelsen EM, Wesselink AK, Hahn KA, Wise LA. Body mass index, physical activity and fecundability in a North American preconception cohort study. Fertil Steril. 2016 Aug;106(2):451-9. doi: 10.1016/j.fertnstert.2016.04.011

Vass C, Gray E, Payne K. Discrete choice experiments of pharmacy services: a systematic review. Int J Clin Phar. 2016 Jun;38(3):620-30. doi: 10.1007/s11096-015-0221-1

Hawe E, Mcbride D, Balp MM, Tian H, Halliday A, Stull DE. EQ-5D utilities in chronic spontaneous/idiopathic urticaria. Pharmacoeconomics. 2016 May;34(5):521-7. doi: 10.1007/s40273-015-0375-7

Herring W, Pearson I, Purser M, Nakhaipour HR, Haiderali A, Wolowacz S, Jayasundara K. Cost effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukaemia in Canada. Pharmacoeconomics. 2016 Jan;34(1):77-90. doi: 10.1007/s40273-01509332-5

Poonawalla IB, Parikh RC, Du XL, VonVille HM, Lairson DR. Cost effectiveness of chemotherapeutic agents and targeted biologics in ovarian cancer: a systematic review. Pharmacoeconomics. 2015 Nov;33(11):1155-85. doi: 10.1007/s40273-015-0304-9

Wise LA, Mikkelsen EM, Sorensen HT, Rothman KJ, Hahn KA, Riis AH, Hatch EE. Prospective study of time to pregnancy and adverse birth outcomes. Fertil Steril. 2015 Apr;103(4):1065-73. doi: 10.1016/j.fertnstert.2015.01.024

Lairson DR, Parikh RC, Cormier JN, Wenyaw C, Du XL. Cost-utility analysis of chemotherapy regimens in elderly patients with stage III colon cancer. Pharmacoeconomics. 2014 Oct;32(10):1005-13.

Brogan AJ, Smets E, Mauskopf JA, Manuel SA, Adriaenssen I. Cost-effectiveness of darunavir/ritonavir combination antiretroviral therapy for treatment-naive adults with HIV-1 infection in Canada. Pharmacoeconomics. 2014 Sep;32(9):903-17.

Radin RG, Hatch EE, Rothman KJ, Mikkelsen EM, Sørensen HT, Riis AH, Wise LA. Active and passive smoking and fecundability in Danish pregnancy planners. Fertil Steril. 2014 Jul;102(1):183-191.e. doi: 10.1016/j.fertnstert.2014.03.018

Rothman KJ, Wise LA, Sorensen HT, Riis AH, Mikkelsen EM, Hatch EE. Volitional determinants and age-related decline in fecundability: a general population prospective cohort study in Denmark. Fertil Steril. 2013 Jun;99(7):1958-64.

Earnshaw SR, Brogan AP, McDade CL. Model-based cost-effectiveness analyses for prostate cancer chemoprevention : a review and summary of challenges. Pharmacoeconomics. 2013 Apr 1;31(4):289-304.

Mauskopf J, Brodan A, Martin S, Smets E. Cost effectiveness of darunavir/ritonavir in highly treatment-experienced, HIV-1-infected adults in the USA. Pharmacoeconomics. 2012 Oct;28 Suppl 1:83-105. doi: 10.2165/11587470-000000000-00000

Wise LA, Rothman KJ, Mikkelsen EM, Sorensen HT, Riis AH, Hatch EE. A prospective cohort study of physical activity and time to pregnancy. Fertil Steril. 2012 May 1;97(5):1136-42.

Talbird SE, Mauskopf J, Smets E, Brogan AJ. US cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, HIV-infected adults with evidence of protease inhibitor resistance included in the TITAN Trial. Pharmacoeconomics. 2010 Dec 23;28(Suppl 1):129-46.

Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics. 2010 Nov 1;28(11):1025-39.

Lynen R, Taylor TN, Farkouh RA, Candrilli SD, Graham J, Colligs A. The effect of age, race, and folic acid-containing supplements on red blood cell folate levels among United States women of child bearing age. Poster presented at the ASRM Annual Meeting; October 26, 2010. [abstract] Fertil Steril. 2010 Sep; 94(4, Suppl 1):S93. doi: 10.1016/j.fertnstert.2010.07.392

Lynen R, Farkouh RA, Taylor TN, Graham J, Colligs A, Lindemann M. Potential impact of using folate-fortified oral contraceptives on risk of neural tube defects in the United States. Poster presented at the 2010 ASRM Annual Meeting; October 2010. [abstract] Fertil Steril. 2010 Sep; 94((4) Suppl 1):S5.

Earnshaw SR, McDade CL, Black LK, Bell CF, Kattan MW. Cost effectiveness of 5-alpha reductase inhibitors for the prevention of prostate cancer in multiple patient populations. Pharmacoeconomics. 2010 Jun 1;28(6):489-505.

Wolowacz SE, Roskell N, Kelly S, Maciver FM, Brand CS. Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK. Pharmacoeconomics. 2007 Oct 1;25(10):863-79.

Shih YCT, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics. 2007 Jul 1;25(7):577-90.

Beard SM, Wall L, Gaffney L, Sampson F. Aggressive non-Hodgkin's lymphoma: economics of high-dose therapy. Pharmacoeconomics. 2004 Jan 1;22(4):207-24.

Bann CM, Fehnel S, Gagnon DD. Development and validation of the diabetic foot ulcer scale-short form (DFS-SF). Pharmacoeconomics. 2003 Jan 1;21(17):1277-90.

Earnshaw SR, Dennett SL. Integer/linear mathematical programming models: a tool for allocating healthcare resources. Pharmacoeconomics. 2003 Jan 1;21(12):839-51.